M&A Deal Summary |
|
|---|---|
| Date | 2016-02-04 |
| Target | Quotient Bioresearch |
| Sector | Life Science |
| Buyer(s) | Pharmaron |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2004 |
| Sector | Life Science |
| Employees | 22,908 |
| Revenue | 12.3B CNY (2024) |
Pharmaron is a publicly owned, premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism, clinical pharmacology, clinical analytical sciences, clinical CRO and SMO, to chemical & pharmaceutical development. With over 10,000 employees, and operations in China, the United States, and the United Kingdom, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan, and China. Pharmaron was founded in 2004 and is based in Beijing, China.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 5 |
| Sector: Life Science M&A | 1 of 5 |
| Type: Add-on Acquisition M&A Deals | 1 of 4 |
| Country: United Kingdom M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-01-10 |
Xceleron
Germantown, Maryland, United States Xceleron, Inc. is a developer of a new preclinical and clinical investigations around the unique analytical features of AMS. With increased adoption, Xceleron developed a proprietary approach to ensure analytical robustness at the very low levels of detection compared to complimentary traditional platforms such as LC-MS/MS and Liquid Scintillation Counting. |
Buy | - |
